ERBB2 and gastroesophageal junction adenocarcinoma: Based on these results, the U.S. FDA approved trastuzumab deruxtecan for patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who failed prior trastuzumab-based treatment on January 15, 2021.76